Beam Therapeutics Inc
NASDAQ:BEAM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
21.22
45.07
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BEAM stock under the Base Case scenario is 9.64 USD. Compared to the current market price of 25.05 USD, Beam Therapeutics Inc is Overvalued by 62%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Beam Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BEAM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Beam Therapeutics Inc
Balance Sheet Decomposition
Beam Therapeutics Inc
Current Assets | 945.5m |
Cash & Short-Term Investments | 925.8m |
Other Current Assets | 19.8m |
Non-Current Assets | 225.8m |
PP&E | 218.2m |
Other Non-Current Assets | 7.6m |
Current Liabilities | 166.2m |
Accounts Payable | 3.8m |
Accrued Liabilities | 64.7m |
Other Current Liabilities | 97.7m |
Non-Current Liabilities | 213.8m |
Other Non-Current Liabilities | 213.8m |
Earnings Waterfall
Beam Therapeutics Inc
Revenue
|
349.6m
USD
|
Operating Expenses
|
-532.3m
USD
|
Operating Income
|
-182.7m
USD
|
Other Expenses
|
39.1m
USD
|
Net Income
|
-143.6m
USD
|
Free Cash Flow Analysis
Beam Therapeutics Inc
USD | |
Free Cash Flow | USD |
BEAM Profitability Score
Profitability Due Diligence
Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
BEAM Solvency Score
Solvency Due Diligence
Beam Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Beam Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BEAM Price Targets Summary
Beam Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BEAM is 50.27 USD with a low forecast of 23.23 USD and a high forecast of 84 USD.
Dividends
Current shareholder yield for BEAM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BEAM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. The company is headquartered in Cambridge, Massachusetts and currently employs 341 full-time employees. The company went IPO on 2020-02-06. The firm is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. The firm has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301.
Contact
IPO
Employees
Officers
The intrinsic value of one BEAM stock under the Base Case scenario is 9.64 USD.
Compared to the current market price of 25.05 USD, Beam Therapeutics Inc is Overvalued by 62%.